[Treatment of early rheumatoid arthritis with a combination of TNF-alpha inhibitors and methotrexate, versus methotrexate alone]

The Regional Health Technology Assessment Centre (HTA-centrum)
Record ID 32011001698
English
Authors' objectives:

Is treatment with TNF-alpha inhibitors and methotrexate better regarding effect on disease activity, physical function, bone alterations, quality of life, and ability to work, compared to treatment with methotrexate alone, in patients with early rheumatoid arthritis (RA) with high disease activity and negative prognostic factors?

Authors' recommendations: There is limited scientific support for a clinically relevant positive effect, by addition of a TNF-alpha inhibitor to methotrexate, for treatment of patients with early rheumatoid arthritis and unfavorable prognostic signs. The direct cost of the introduction is expected amount to about 10 MSEK/year in Västra Götaland Region. In addition, it is difficult to estimate restructuring costs in the health care organization. The side effect issue is considered manageable, taking into account the severity of the disease.
Details
Project Status: Completed
Year Published: 2009
English language abstract: An English language summary is available
Publication Type: Not Assigned
MeSH Terms
  • Antirheumatic Agents
  • Arthritis, Rheumatoid
  • Methotrexate
  • Tumor Necrosis Factor-alpha
Contact
Organisation Name: The Regional Health Technology Assessment Centre
Contact Address: The Regional Health Technology Assessment Centre, Region Vastra Gotaland, HTA-centrum, Roda Straket 8, Sahlgrenska Universitetssjukhuset, 413 45 GOTHENBORG, Sweden
Contact Name: hta-centrum@vgregion.se
Contact Email: hta-centrum@vgregion.se
Copyright: The Regional Health Technology Assessment Centre (HTA-centrum), Region Vastra Gotaland
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.